Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002147
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Use of Stealth Liposomal Doxorubicin HCl DOX-SL in the Treatment of Moderate to Severe AIDS-Related Kaposis Sarcoma
Sponsor:
Sequus Pharmaceuticals
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Use of Stealth Liposomal Doxorubicin HCl DOX-SL in the Treatment of Moderate to Severe AIDS-Related Kaposis Sarcoma
Status:
COMPLETED
Status Verified Date:
1996-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To provide Stealth liposomal doxorubicin hydrochloride DOX-SL as a therapy for Kaposis sarcoma patients who have no remaining treatment options other than DOX-SL or patients who have been participating in another DOX-SL protocol and for whom continuation in DOX-SL is medically indicated Also to evaluate the safety and efficacy of DOX-SL in patients with Kaposis sarcoma who have previously received systemic chemotherapy with or without an anthracycline
Detailed Description:
Patients receive DOX-SL every 3 weeks for up to 20 cycles
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| LTI-30-25 | None | None | None |